Press Releases


Aladdin Healthcare Technologies SE has developed a novel prototype application for more accurate real-time diagnosis of COVID-19 Corona Virus

BERLIN/LONDON, 3 March 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN:DE000A12ULL2), a leading developer of A.I healthcare diagnostics and drug discovery applications for age-related diseases, has successfully completed a working A.I prototype for detecting COVID-19 and already started working with multiple healthcare institutions in China to integrate its diagnostic technology. The Company is in cooperation with several hospitals in Wuhan, Shenzhen and Guangzhou China with other cities planned. Aladdin is set to become a key global A.I solution provider for real-time diagnosis of Coronavirus.

China and the world have been overwhelmed by the recent outbreak of a mutated version of the Coronavirus (COVID-19), which has resulted in unprecedented pressure on doctors, culminating in severe patient congestion and delayed diagnosis.

As a solution, Aladdin will provide doctors with a real-time A.I application that can act as an assistive tool to make a more accurate diagnosis, thereby alleviating workload and diagnosing patients faster.

It solves three major challenges to diagnose COVID-19:

  • It reduces the workload of doctors through the automatic generation of A.I assisted diagnosis reports in only 2-3 seconds instead of 5 to 6 hours. Distinguishing COVID-19 from other pulmonary diseases and healthy individuals at a very high degree of diagnostic accuracy.
  • Automatically detects and highlights lesion areas for COVID-19 and grades the disease severity in real time.

The problem currently lies in the lack of a unified and rapid standard, especially in the core epidemic areas, which leads to inefficient manual diagnostic methods used by doctors for quantitative evaluation. The sudden and overwhelming medical needs in China have resulted in patient congestion accompanied by panic. Furthermore, it is difficult for doctors to rapidly distinguish the new Coronavirus from other pneumonia diseases by the only use of CT imaging (Computer Tomography scan).

The Aladdin’s method provides doctors with a new generation, real-time application, which assures a high accuracy in the disease diagnosis process. Aladdin’s A.I solution is based on a multimodal approach that uses multi-omics data and CT image data. Through its advanced method, Aladdin can fight Coronavirus, saving time and improving diagnostic accuracy.

“This is a great achievement for us. Based on this success, we have demonstrated our capability of providing accurate A.I solutions for complex diseases,” said Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE. “We have also been informed that the hospital group in Hangzhou wants to further expand the validation of our A.I model for the early detection of Alzheimer’s Disease, cardiovascular disease and other diseases. This validates our tech and underpins our ability to execute on our plan about the 2020 milestones.”

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by the award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, the AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.